莫西沙星联合头孢哌酮钠舒巴坦钠对重症肺炎患者炎症及氧化应激反应的影响

Impacts of moxifloxacin combined with cefoperazone sodium and sulbactam sodium on inflammation and oxidative stress reactions in patients with severe pneumonia

目的观察莫西沙星联合头孢哌酮钠舒巴坦钠对重症肺炎(SP)患者炎症及氧化应激反应的影响。方法选择2016年2月至2019年12月于湖北省荆州市胸科医院呼吸与危重症医学科住院治疗的74例SP患者作为研究对象,按随机数字表法分为两组,每组各37例,两组患者入院后均予以对症支持措施治疗,对照组在此基础上予以头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上加用莫西沙星治疗,两组疗程均为2周。比较两组患者疗效及抗生素治疗时间、发热消退时间、机械通气治疗时间、ICU住院时间等临床相关指标改善情况,检测两组患者治疗前后炎症及氧化应激反应相关指标水平变化。结果对照组治疗总有效率为64.86%,观察组治疗总有效率为86.49%,两组治疗总有效率比较,差异有统计学意义(P<0.05);观察组抗生素治疗时间、发热消退时间、机械通气治疗时间及ICU住院时间均短于对照组,差异有统计学意义(P<0.05);两组治疗前炎症及氧化应激反应相关指标比较,差异无统计学意义(P>0.05),两组治疗后白介素(IL)-2、IL-4、CRP及丙二醛(MDA)均降低,而超氧化物歧化酶(SOD)、脂质过氧化氢(LHP)均升高,差异有统计学意义(P<0.05),且治疗后观察组IL-2、IL-4、CRP及MDA指标低于对照组,而SOD、LHP指标高于对照组,差异有统计学意义(P<0.05)。结论莫西沙星联合头孢哌酮钠舒巴坦钠治疗SP疗效显著,可明显减轻患者炎症及氧化应激反应,从而促进患者病情尽快恢复。

Objective To observe the impacts of moxifloxacin combined with cefoperazone sodium and sulbactam sodium on inflammation and oxidative stress reactions in patients with severe pneumonia(SP). Methods A total of 74 patients with SP admitted to the department of respiratory and critical care medicine of Jingzhou Chest Hospital of Hubei Province from February 2016 to December 2019 were selected as the research objects, and they were divided into the control group(n=37) and the observation group(n=37) according to the random number table method. Both groups of patients were treated with symptomatic support measures after admission, and the control group was treated with cefoperazone sodium and sulbactam sodium on this basis, while the observation group was treated with moxifloxacin on the basis of the control group. The course of treatment in both groups was two weeks. The therapeutic efficacy and the improvement of clinical related indexes such as antibiotic treatment time, fever subsided time, mechanical ventilation treatment time and ICU hospitalization time were compared, and the level changes of inflammation and oxidative stress reactions related indexes before and after treatment were detected between the two groups of patients. Results The total efficacy rate of treatment in the control group was 64.86%, and that in the observation group was 86.49%, with statistically significant difference between the two groups(P < 0.05). The antibiotic treatment time, fever subsided time, mechanical ventilation treatment time and ICU hospitalization time in the observation group were shorter than those in the control group, with statistically significant differences(P < 0.05). Before treatment, there was no statistically significant difference in the related indexes of inflammation and oxidative stress reactions between the two groups(P > 0.05). After treatment, the IL-2, IL-4, CRP and MDA were all decreased, while SOD and LHP were both increased, with statistically significant differences(P<0.05). Meanwhile, the indexes of IL-2, IL-4, CRP and MDA in the observation group were lower than those in the control group, while the indexes of SOD and LHP in the observation group were higher than those in the control group, with statistically significant differences(P < 0.05). Conclusion Moxifloxacin combined with cefoperazone sodium and sulbactam sodium is effective in the treatment of SP, which can obviously reduce the inflammation and oxidative stress reactions of patients, thus promoting their recovery as soon as possible.